Liquid biopsy = Individualized cancer management: Diagnosis, monitoring treatment and checking recurrence and metastasis

Oral Oncology ◽  
2021 ◽  
Vol 123 ◽  
pp. 105588
Author(s):  
Shrikant Balasaheb Mali ◽  
Sachinkumar Dahivelkar
Keyword(s):  
Liquid Biopsy ◽  
Cancer Management ◽  
Management Diagnosis ◽  
Monitoring Treatment

scholarly journals Molecular Profiling of Malignant Pleural Effusions with Next Generation Sequencing (NGS): Evidence that Supports Its Role in Cancer Management

2020 ◽  
Vol 10 (4) ◽  
pp. 206
Author(s):  
Georgia Ι. Grigoriadou ◽  
Stepan M. Esagian ◽  
Han Suk Ryu ◽  
Ilias P. Nikas
Keyword(s):  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Liquid Biopsy ◽  
Molecular Profiling ◽  
Pleural Effusions ◽  
Advanced Cancer Patients ◽  
Cancer Management ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing

Malignant pleural effusions (MPEs) often develop in advanced cancer patients and confer significant morbidity and mortality. In this review, we evaluated whether molecular profiling of MPEs with next generation sequencing (NGS) could have a role in cancer management, focusing on lung cancer. We reviewed and compared the diagnostic performance of pleural fluid liquid biopsy with other types of samples. When applied in MPEs, NGS may have comparable performance with corresponding tissue biopsies, yield higher DNA amount, and detect more genetic aberrations than blood-derived liquid biopsies. NGS in MPEs may also be preferable to plasma liquid biopsy in advanced cancer patients with a MPE and a paucicellular or difficult to obtain tissue/fine-needle aspiration biopsy. Of interest, post-centrifuge supernatant NGS may exhibit superior results compared to cell pellet, cell block or other materials. NGS in MPEs can also guide clinicians in tailoring established therapies and identifying therapy resistance. Evidence is still premature regarding the role of NGS in MPEs from patients with cancers other than lung. We concluded that MPE processing could provide useful prognostic and theranostic information, besides its diagnostic role.

Liquid biopsy leads to a paradigm shift in cancer treatment.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 602-602
Author(s):  
Koichi Suzuki ◽  
Yuji Takayama ◽  
Kosuke Ichida ◽  
Taro Fukui ◽  
Nao Kakizawa ◽  
...  
Keyword(s):  
Liquid Biopsy ◽  
Multiple Testing ◽  
Poor Response ◽  
Digital Pcr ◽  
Circulating Tumor Dna ◽  
Initial Assessment ◽  
Tumor Tissues ◽  
Time Changes ◽  
Colorectal Cancer Patients ◽  
Monitoring Treatment

602 Background: Liquid biopsy represents an ideal non-invasive tool allowing multiple testing over time, monitoring real time changes occurring within the tumor and evaluation of therapeutic response. Here we show monitoring of KRAS mutation in detection of circulating tumor DNA (ctDNA) during treatments for metastatic colorectal cancer patients (pts). Methods: 238 plasma samples were collected from 57 pts who underwent chemotherapy. KRAS mutant ctDNA (MctDNA) was determined by digital PCR as a tool of Liquid biopsy, detecting rare mutant clones in blood. Results: KRAS assessment in tumor tissues showed 19 pts with mutation (M) and 38 without mutation (W). Among 19 pts with M, 12 pts displayed MctDNA at the initial assessment and 7 pts showed no MctDNA. Then, one (M*) of 7 pts exhibited MctDNA during treatments. While 38 pts with W showed no MctDNA before chemotherapy except one pt (M**), 4 pts exhibited MctDNA after treatments with different regimens. MctDNA was detectable in the blood of these 4 pts prior to radiographic detection of disease progression. Regardless of KRAS status in tumor tissues, poor response was seen in pts with MctDNA. Conclusions: Liquid biopsy provides us a circulating biomarker for monitoring treatment response and choice of optimal regimens. [Table: see text]

The role of liquid biopsies in prostate cancer management

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Chi-Ju Kim ◽  
Liang Dong ◽  
Sarah Amend ◽  
Yoon-Kyoung Cho ◽  
Kenneth Pienta
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cancer Diagnosis ◽  
Liquid Biopsy ◽  
Liquid Biopsies ◽  
Cancer Management ◽  
The Common ◽  
Prostate Cancer Management

Liquid biopsy has emerged as a complement to invasive tissue biopsy to guide cancer diagnosis and treatment. The common liquid biopsy biomarkers are circulating tumor cells (CTCs), extracellular vesicles (EVs),...

scholarly journals Refining Cancer Management Using Integrated Liquid Biopsy

Theranostics ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 2374-2384 ◽  
Author(s):  
Juhui Qiu ◽  
Jianxiong Xu ◽  
Kang Zhang ◽  
Wei Gu ◽  
Liming Nie ◽  
...  
Keyword(s):  
Liquid Biopsy ◽  
Cancer Management

Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis

2018 ◽  
Vol 73 (4) ◽  
pp. 535-540 ◽  
Author(s):  
Karin Birkenkamp-Demtröder ◽  
Emil Christensen ◽  
Iver Nordentoft ◽  
Michael Knudsen ◽  
Ann Taber ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Response ◽  
Liquid Biopsy ◽  
Metastatic Relapse ◽  
Advanced Bladder Cancer ◽  
Monitoring Treatment ◽  
Monitoring Treatment Response

scholarly journals Liquid Biopsy Prevents Inaccurate Her2 Status Determination by in situ Hybridization in a Patient with Invasive Ductal Adenocarcinoma of the Breast: Case Report

2017 ◽  
Vol 10 (3) ◽  
pp. 857-862 ◽  
Author(s):  
Yen-Dun Tony  Tzeng ◽  
Shih-En Chang ◽  
Rui Mei ◽  
Manana  Javey 
Keyword(s):  
Case Report ◽  
Liquid Biopsy ◽  
Circulating Tumor Dna ◽  
Cancer Surveillance ◽  
Ductal Adenocarcinoma ◽  
Her2 Status ◽  
Noninvasive Test ◽  
Cancer Management ◽  
Area Of Interest ◽  
Invasive Ductal Adenocarcinoma

Utilization of circulating tumor DNA as a novel and noninvasive test for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In the wake of FDA approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical utility of liquid biopsy for cancer management throughout the course of the disease. This case report describes a female with invasive ductal adenocarcinoma of the breast, where liquid biopsy was instrumental for her cancer characterization and personalized therapy selection.

scholarly journals Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2277 ◽  
Author(s):  
Hiu Ting Chan ◽  
Yoon Ming Chin ◽  
Yusuke Nakamura ◽  
Siew-Kee Low
Keyword(s):  
Cancer Patients ◽  
Liquid Biopsy ◽  
Somatic Mosaicism ◽  
Hematopoietic Stem ◽  
Molecular Alterations ◽  
Cancer Management ◽  
Clonal Hematopoiesis ◽  
Increased Risk ◽  
Incorrect Classification

The use of blood liquid biopsy is being gradually incorporated into the clinical setting of cancer management. The minimally invasive nature of the usage of cell-free DNA (cfDNA) and its ability to capture the molecular alterations of tumors are great advantages for their clinical applications. However, somatic mosaicism in plasma remains an immense challenge for accurate interpretation of liquid biopsy results. Clonal hematopoiesis (CH) is part of the normal process of aging with the accumulation of somatic mutations and clonal expansion of hematopoietic stem cells. The detection of these non-tumor derived CH-mutations has been repeatedly reported as a source of biological background noise of blood liquid biopsy. Incorrect classification of CH mutations as tumor-derived mutations could lead to inappropriate therapeutic management. CH has also been associated with an increased risk of developing cardiovascular disease and hematological malignancies. Cancer patients, who are CH carriers, are more prone to develop therapy-related myeloid neoplasms after chemotherapy than non-carriers. The detection of CH mutations from plasma cfDNA analysis should be cautiously evaluated for their potential pathological relevance. Although CH mutations are currently considered as “false-positives” in cfDNA analysis, future studies should evaluate their clinical significance in healthy individuals and cancer patients.

Circulating Tumor DNA: A Step into the Future of Cancer Management

2019 ◽  
Vol 63 (6) ◽  
pp. 456-465 ◽  
Author(s):  
Joana Fernandes Marques ◽  
Joana Pereira Reis ◽  
Gabriela Fernandes ◽  
Venceslau Hespanhol ◽  
José Carlos Machado ◽  
...  
Keyword(s):  
Liquid Biopsy ◽  
Clinical Utility ◽  
New Technologies ◽  
Therapy Response ◽  
Circulating Tumor Dna ◽  
Sample Collection ◽  
Cancer Management ◽  
The Past ◽  
Ctdna Analysis ◽  
Tumor Dna

Liquid biopsy was introduced to the oncology field with the promise of revolutionizing the management of cancer patients, minimizing the exposure to invasive procedures such as tissue biopsy, and providing reliable information regarding therapy response and detection of disease relapse. Despite the significant increase in the number of published studies on circulating tumor DNA (ctDNA) in the past years, the emphasis of most studies is on the development of new technologies or on the clinical utility of ctDNA. This leaves a clear gap of knowledge concerning the biology of ctDNA, such as the fundamental mechanisms through which DNA from tumor cells is released into the circulation. Moreover, considering that ctDNA analysis is now currently being applied in clinical practice, the need for rigorous quality control is arising, and with it the necessity to standardize procedures, from sample collection to data analysis. This review focuses on the main aspects of ctDNA, including approaches currently available to evaluate tumor genetics, as well as the points that still require improvement in order to make liquid biopsy a key player in precision medicine.

Sign in / Sign up

Export Citation Format

Share Document